Drugs / 1-desamino-8-Darginine vasopressin
1-desamino-8-Darginine vasopressin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03379974 | Jul 2018 → Aug 2019 | hemophilia A | Nationwide Children's Hospital | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 1-desamino-8-Darginine vasopressin | “FVIII levels temporarily rise with stress, exercise and with DDAVP (1-desamino-8-Darginine vasopressin, desmopressin).” NCT03379974 ↗ |
| Known as | DDAVP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03379974 ↗ |
| Known as | desmopressin | “FVIII levels temporarily rise with stress, exercise and with DDAVP (1-desamino-8-Darginine vasopressin, desmopressin).” NCT03379974 ↗ |
| Known as | IN DDAVP | “For the DDAVP intervention the participant will take either 1 or 2 nasal sprays of IN DDAVP.” NCT03379974 ↗ |
| Route | Intranasal | “take either 1 or 2 nasal sprays of IN DDAVP” NCT03379974 ↗ |